Send to

Choose Destination
See comment in PubMed Commons below

Microbubbles coated with biotinylated rabbit anti-mouse endoglin monoclonal antibody.


Chopra A1.


Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2011 Sep 06 [updated 2011 Sep 29].

Author information

National Center for Biotechnology Information, NLM, Bethesda, MD 20894


Angiogenesis, the development of new vasculature from pre-existing blood vessels (for details see Carmeliet and Jain (1)), is essential for the development, maintenance, progression, and metastasis of neoplastic tumors (2). Therefore, angiogenesis is considered to be the hallmark of cancerous tumors, and early detection of this process can facilitate the initiation of treatment and management of the disease (3). Although there are several known pro-angiogenic biomarkers, among these only endoglin (4), αVβ3 integrin (5), and the vascular endothelial growth factor receptor 2 (VEGFR-2) (6) are well characterized and are overexpressed in many cancerous tumors, such as those of the breast, ovaries, and the pancreas (3). Endoglin (CD105) is a co-receptor of the transforming growth factor beta (TGF-β) and co-modulates the different activities, including angiogenesis, of the activated TGF-β receptor (7). The αVβ3 integrin is a G-protein–coupled receptor that can bind several different ligands such as fibronectin, von Willebrand factor, fibrinogen, etc., and assists with the survival and migration of cancerous cells, which increases the invasive potential of cancerous cells, and promotes angiogenesis in tumors (8). The VEGFR-2 mediates its effects through a family of receptor tyrosine kinases that promote the mitogenesis, survival, differentiation, migration, and vascular permeability of endothelial cells (9). Little information is available regarding the expression of the different angiogenic markers during the progression of a tumor from a small size to a larger size, and the noninvasive visualization of angiogenic markers that are overexpressed during initial stages of the neoplasia can facilitate early detection and treatment of the disease (3). For this, Deshpande et al. developed a series of microbubble (MB; perfluorocarbon gas enclosed within spherical lipid shells harboring streptavidin moieties to bind biotinylated monoclonal antibodies (mAb) directed toward specific targets)–based contrast agents that were coated with specific antibodies targeted to endoglin (MBendoglin), αVβ3 integrin (MBintegrin), and VEGFR 2 (MBvegfr2), respectively (3). The targeted MBs were then used with ultrasound imaging to determine the expression of the angiogenic antigens during the growth of human ovarian (SKOV3 cells), human breast (MDA-MB-361 cells), and human pancreatic (MiaPaCa2 cells) cell line xenograft tumors in mice. This chapter describes the studies performed with MBendoglin. Studies performed with MBintegrin and MBvegfr2 are described in separate chapters of MICAD ( (10, 11).

PubMed Commons home

PubMed Commons

How to join PubMed Commons
    Support Center